SHANGHAI JUNSHI BIOSCIENCES CO., LTD. Financials Shanghai Junshi Biosciences Co., Ltd. Shanghai S.E.
Equities
688180
CNE1000041Z1
Pharmaceuticals
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 28.68 CNY | -1.04% |
|
-5.66% | -31.44% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 18,711 | 64,649 | 56,686 | 57,119 | 35,947 | 24,304 | - | - |
| Enterprise Value (EV) 1 | 18,402 | 62,115 | 53,714 | 52,363 | 33,904 | 21,265 | 21,928 | 22,349 |
| P/E ratio | -24.9 x | -23.4 x | -59.1 x | - | -7.62 x | -6.76 x | -9.11 x | -11.2 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 24.1 x | 40.5 x | 14.1 x | 39.3 x | 23.9 x | 11.4 x | 9.91 x | 8.2 x |
| EV / Revenue | 23.7 x | 38.9 x | 13.3 x | 36 x | 22.6 x | 9.99 x | 8.95 x | 7.54 x |
| EV / EBITDA | -23.5 x | -41.7 x | -127 x | -21.7 x | -16 x | -15.6 x | -21.8 x | -25.4 x |
| EV / FCF | -9.3 x | -30.5 x | -38 x | -24.1 x | -12.8 x | -10.5 x | -13.2 x | -16 x |
| FCF Yield | -10.8% | -3.28% | -2.63% | -4.14% | -7.8% | -9.5% | -7.57% | -6.24% |
| Price to Book | 6.26 x | 7.14 x | 5.17 x | - | 2.43 x | 1.49 x | 1.63 x | 1.55 x |
| Nbr of stocks (in thousands) | 784,147 | 872,496 | 910,757 | 982,872 | 985,011 | 984,908 | - | - |
| Reference price 2 | 23.86 | 47.81 | 47.26 | 42.83 | 17.67 | 10.70 | 10.70 | 10.70 |
| Announcement Date | 20-03-02 | 21-02-26 | 22-02-25 | 23-02-27 | 24-02-23 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 775.1 | 1,595 | 4,025 | 1,453 | 1,503 | 2,129 | 2,451 | 2,963 |
| EBITDA 1 | -783.5 | -1,490 | -422 | -2,417 | -2,122 | -1,360 | -1,008 | -880 |
| EBIT 1 | -747.3 | -1,636 | -558.3 | -2,666 | -2,377 | -1,581 | -868.7 | -1,129 |
| Operating Margin | -96.41% | -102.59% | -13.87% | -183.41% | -158.19% | -74.27% | -35.44% | -38.11% |
| Earnings before Tax (EBT) 1 | -763.1 | -1,672 | -595 | -2,677 | -2,490 | -1,538 | -767.7 | -43.62 |
| Net income 1 | -747.4 | -1,669 | -720.9 | -2,388 | -2,282 | -1,433 | -717.5 | -85.17 |
| Net margin | -96.43% | -104.62% | -17.91% | -164.3% | -151.85% | -67.29% | -29.27% | -2.87% |
| EPS 2 | -0.9600 | -2.040 | -0.8000 | - | -2.320 | -1.583 | -1.175 | -0.9566 |
| Free Cash Flow 1 | -1,979 | -2,037 | -1,414 | -2,170 | -2,643 | -2,021 | -1,661 | -1,395 |
| FCF margin | -255.28% | -127.71% | -35.14% | -149.31% | -175.92% | -94.92% | -67.76% | -47.09% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 20-03-02 | 21-02-26 | 22-02-25 | 23-02-27 | 24-02-23 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: |
|---|
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 309 | 2,534 | 2,972 | 4,756 | 2,043 | 3,039 | 2,377 | 1,956 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -1,979 | -2,037 | -1,414 | -2,170 | -2,643 | -2,014 | -1,661 | -1,395 |
| ROE (net income / shareholders' equity) | -23.6% | -37.7% | -10.4% | -32.7% | -27.4% | -23.1% | -11.5% | -0.15% |
| ROA (Net income/ Total Assets) | -17.1% | -26.8% | -9.24% | - | -19.1% | -14.7% | -6.78% | -0.61% |
| Assets 1 | 4,360 | 6,228 | 7,802 | - | 11,969 | 9,766 | 10,589 | 13,863 |
| Book Value Per Share 2 | 3.810 | 6.690 | 9.150 | - | 7.270 | 7.200 | 6.550 | 6.890 |
| Cash Flow per Share 2 | -0.9100 | -1.780 | -0.7200 | - | -2.050 | -1.220 | -0.5700 | - |
| Capex 1 | 792 | 580 | 772 | 394 | 628 | 610 | 610 | 400 |
| Capex / Sales | 102.13% | 36.4% | 19.19% | 27.1% | 41.81% | 28.63% | 24.87% | 13.5% |
| Announcement Date | 20-03-02 | 21-02-26 | 22-02-25 | 23-02-27 | 24-02-23 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
10.7
CNY
Average target price
22.59
CNY
Spread / Average Target
+111.16%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +2.26% | 93.53B | |
| -1.71% | 38.27B | |
| -12.83% | 32.84B | |
| -12.14% | 16.08B | |
| -0.68% | 14.02B | |
| -12.63% | 11.47B | |
| +163.45% | 9.92B | |
| -53.23% | 9.42B | |
| +3.52% | 8.98B |
- Stock Market
- Equities
- 1877 Stock
- 688180 Stock
- Financials Shanghai Junshi Biosciences Co., Ltd.
